U.S. Physical Therapy, Inc.
NYSE:USPHMedical - Care Facilities
+$0.12 today
- Market cap
- $1.42B
- Beta
- 1.16
- P/E (TTM)
- 810.7
- EPS (TTM)
- $0.08
- Dividend yield
- 2.89%
Volume 0.33M
Average 0.20M
USPH Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
U.S. Physical Therapy, Inc.NYSE: USPH
Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026
Cost of revenue growth accelerates
Q1 FY2026 cost of revenue of $169.6M rose 39.6% year over year, ahead of the +7.3% change in trailing-twelve-month cost of revenue. Sequentially, it rose 5.4% from the prior quarter. Over 3 fiscal years it compounded at +12.2% a year.
Context
- Cost of revenue amounted to 79.9% of revenue in FY2025, down 1.7 pp from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +39.6% holds above the trailing-twelve-month pace of +7.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 623.65M USD
- Year-over-year change
- +13.9%
- 4-year CAGR
- +13.3%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 623.65M | +13.9% |
| FY2024 | 2024-12-31 | 547.42M | +13.3% |
| FY2023 | 2023-12-31 | 483.29M | +9.6% |
| FY2022 | 2022-12-31 | 441.12M | +16.7% |
| FY2021 | 2021-12-31 | 377.84M | — |
Cost of Revenue vs competitors
How USPH compares with its peers on the latest reported figures
- USPH's LTM Mar 2026 cost of revenue of $580.17M is the 7th highest of the 11 companies compared; the peer median is $754.42M.
- Its year-over-year change of +7.3% is the 9th highest of 11, against a peer median of +25.9%.
- Cost of revenue amounts to 79.6% of revenue for USPH, versus a peer median of 85.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.93B | +28.0% | -4.9% | 89.4% | |
| LTM Mar 2026 | $3.2B | +61.8% | +45.1% | 90.7% | |
| LTM Apr 2026 | $2.71B | +8.1% | +1.6% | 94.6% | |
| LTM Mar 2026 | $1.6B | +6.1% | +2.2% | 86.4% | |
| LTM Mar 2026 | $871.95M | +35.1% | +25.8% | 85.2% | |
| LTM Mar 2026 | $636.88M | +8.8% | +11.0% | 46.4% | |
| LTM Mar 2026 | $580.17M | +7.3% | +12.2% | 79.6% | |
| LTM Aug 2026 | $465.01M | -11.0% | +3.5% | 52.6% | |
| LTM Mar 2026 | $105.91M | +115.7% | -4.0% | 13.4% | |
| LTM Mar 2026 | $103.75M | +54.1% | — | — | |
| LTM Jan 2026 | $42.91M | +23.8% | — | 51.2% | |
| Peer median (excluding USPH) | $754.42M | +25.9% | +2.9% | 85.2% | |
Competitors are the stored peer set for USPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 495.02M | 553.14M | 604.8M | 671.35M | 780.99M |
| Cost of Revenue | 377.84M | 441.12M | 483.29M | 547.42M | 623.65M |
| Gross Profit | 117.18M | 112.02M | 121.51M | 123.92M | 157.34M |
| Gross Margin | 23.7% | 20.3% | 20.1% | 18.5% | 20.1% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 46.53M | 46.11M | 0 | 58.29M | 0 |
| Operating Expenses | 46.53M | 55.22M | 69.45M | 60.71M | 76.91M |
| Depreciation & Amortization | 11.59M | 14.74M | 15.7M | 18.68M | 22.39M |
| EBITDA | 85.73M | 76.09M | 74.37M | 86.91M | 109.66M |
| EBITDA Margin | 17.3% | 13.8% | 12.3% | 12.9% | 14.0% |
| Operating Income | 70.65M | 56.8M | 52.06M | 63.21M | 80.43M |
| Operating Margin | 14.3% | 10.3% | 8.6% | 9.4% | 10.3% |
| Interest Income | 0 | 0 | 3.77M | 3.94M | 105K |
| Interest Expense | 942K | 5.78M | 9.3M | 8.02M | 9.46M |
| Other Income / Expenses | 2.55M | (1.23M) | (2.69M) | (3M) | (2.62M) |
| Income Before Tax | 73.2M | 55.57M | 49.38M | 60.21M | 77.81M |
| Pre-Tax Margin | 14.8% | 10.0% | 8.2% | 9.0% | 10.0% |
| Income Tax Expense | 15.27M | 12.16M | 12.16M | 14.61M | 19.81M |
| Net Income | 27.82M | 28.27M | 14.67M | 26.46M | 15.06M |
| Net Margin | 5.6% | 5.1% | 2.4% | 3.9% | 1.9% |
| EPS (Basic) | 4.49 | 3.34 | 1.28 | 1.84 | 1.42 |
| EPS (Diluted) | 4.49 | 3.34 | 1.28 | 1.84 | 1.42 |
| Weighted Avg Shares | 12.9M | 12.99M | 14.19M | 15.06M | 15.18M |
| Weighted Avg Shares (Diluted) | 12.9M | 12.99M | 14.19M | 15.06M | 15.18M |
U.S. Physical Therapy, Inc.
NYSE:USPH
Intrinsic Alpha fair value
Locked
Current Price
$95.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.